Nice, France—September 19th, 2007 – CLL Pharma, a pharmaceutical R&D Company, today announced that the United States Patent and Trademark Office has issued the company a notice of allowance for a patent covering the use of the Pep:trans technology to improve the immune response to antigens (US Application # 10/270,010). This technology, Pep:trans, uses small peptides vectors that are able to enhance the immune response of various antigens including peptide and proteins. Various studies in vitro and in vivo have demonstrated its efficacy in enhancing CTL response in animals (Journal of Immunology.2003, 170:1498-1503).

Claude Laruelle, President and Chief Executive Officer of CLL Pharma, stated, "We are very pleased that this patent has now been issued by both the USPTO and the European Patent Office. We believe that this technology can be a great asset to companies designing vaccines for the treatment or prevention of infectious and malignant diseases”

The technology is now available for licensing.

About Pep:trans

Pep:trans technology is a new approach to intracellular delivery of therapeutic molecules into the cell. It is based on new small peptide-derived vectors (SynB) that are able to cross cell membranes. This allows the delivery of therapeutic molecules to their intracellular target with great efficiency. This technology can also enhance the transport of drugs across the blood-brain barrier where there is a real need for less invasive techniques.
Linking drugs to Pep:trans (or Vectorisation) re-engineers their pharmacokinetic and/or pharmacodynamic profiles. Vectorisation can result in a significant enhancement of brain or cell uptake with associated improvement of pharmacological activity in animal models.
The Pep:trans approach has a broad range of applications and can be of great interest to conventional drugs, peptides and small proteins.


For further information contact:

Contacts
Claude Laruelle, CEO
+33 (0) 4.93.21.85.60
Jamal Temsamani, VP Preclinical R&D
+33 (0) 6.09.58.64.20
jamal.temsamani@cllpharma.com

London, UK 20 February 2007: BTG plc (LSE: BGC), the medical innovations company, today announces that it has licensed an opioid agonist for the control of post-operative pain from CLL Pharma, the drug development company based in Nice, France, in return for undisclosed milestone and royalty payments.

BTG6001 is an orally active opioid agonist with a long duration of action, potentially reducing the amount of analgesic required for effective pain control. Owing to its unique receptor profile, BTG6001 is also expected to show a superior side effect profile compared with current opiate analgesics. BTG plans to complete preclinical development and initiate Phase I clinical studies during 2008.

Louise Makin, BTG’s Chief Executive Officer, said “We believe BTG6001 has significant advantages over current opiates and we plan to develop it for post-operative pain control and potentially other pain indications. This acquisition is in line with our objective of building a strong development pipeline in selected therapy areas, including neuroscience and oncology.”

CLL Pharma’s Chief Executive, Claude Laruelle, commented: “CLL Pharma is seeking to realise the value of its portfolio of products in pain and oncology. We are delighted to have reached this agreement with BTG and are seeking partners for other programmes. We believe BTG is an excellent partner for this programme.”


For further information contact:

BTG :
Andy Burrows, Director of Investor Relations
+44 (0)20 7575 1741; mobile: +44 (0)7990 530605
Christine Soden, Chief Financial Officer
+44 (0)20 7575 1591

Financial Dynamics :
Ben Atwell/Anna Keeble
+44 (0)20 7831 3113

About BTG
BTG in-licenses, develops and commercialises pharmaceuticals and other medical technologies. With a substantial and growing revenue stream of royalties and milestone payments from out-licensed products, BTG continues to strengthen its pipeline of preclinical and clinical development programmes. Active in the fields of oncology, diseases of ageing, neuroscience, drug repositioning and medical devices, BTG works from its offices in London, Philadelphia and Osaka with a global partner network of healthcare companies and research organisations. For further information, visit: www.btgplc.com.

Nice-France, October 10th, 2007. CLL Pharma announced today the notice of allowance of the patent (U.S. Application # 10/492,170) from the United States Patent & Trademark Office, for the use of a nonapeptide (Syn1002) in the treatment of inflammatory and neuropathic pain.

"This patent offers a significant extension to CLL Pharma intellectual property position, opening up the possibility for expanded commercial opportunities," said Claude Laruelle President and CEO of CLL Pharma. "We believe there is significant market potential for the use of Syn1002 for the treatment of inflammatory and neuropathic pain conditions such as arthritis, diabetic neuropathy pain and cancer pain ."

In 2003, CLL Pharma has acquired world-wide rights from INSERM for the use of Syn1002 for inflammatory and neuropathic pain indications. The Company has carried out all the regulatory preclinical studies and the compound is ready to move to Phase I trials.

The Company is looking for a partner to develop Syn1002.

About Syn1002 :
Syn1002 is an analog of thymulin, a nonapeptide that has an immunomodulating role. The pharmacological activity of Syn1002 has been investigated in various animal models of inflammatory and neuropathic pain (Saadé et al. 2003. Neuroscience 119: 155-165). The compound is active at micrograms levels and show a better efficacy than the existing drugs (morphine, COX inhibitors, etc). The Syn1002 mechanism of action suggests an inhibition of pro-inflammatory cytokines such as TNF-alpha and IL-6. All the regulatory preclinical studies were completed and show that Syn1002 is safe and well tolerated in animals. The compound is ready to move to Phase I clinical trials.
For further information contact:

Contacts
Claude Laruelle, CEO
+33 (0) 4.93.21.85.60

Jamal Temsamani, VP Preclinical R&D
+33 (0) 6.09.58.64.20
jamal.temsamani@cllpharma.com

CLL Pharma est heureux de vous présenter son nouveau portail Internet.